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Cytarabine-related lung infiltrates on high resolu-
tion computerized tomography: a possible compli-
cation with benign outcome in leukemic patients
Potentially fatal lung toxicity occurs in 12-20%
of leukemic patients treated with cytarabine espe-
cially at intermediate to high doses, usually pre-
senting as noncardiogenic pulmonary edema
(NCPE). Anecdotally the association between
cytarabine and the onset of bronchiolitis obliterans
organizing pneumonia (BOOP) has been reported.
We describe here three cases of patients affected
by acute myeloid leukemia (AML) treated with
chemotherapeutic regimens including high dose
cytarabine, who developed early onset of fever,
mild dyspnea, moderate hypoxemia on arterial
blood gas analysis and lung infiltrates documented
by high-resolution computerized tomography
(HRCT), with a more indolent behaviour and a
benign clinical outcome, compared with similar
cases previously reported in the literature. Our
cases widen the spectrum of clinical features of
cytarabine-related toxicity in leukemic patients.Haematologica 2007; 92:(9)e85-e90 DOI: 10.3324/haematol.11697
Cytosine arabinoside, a pyrimidine nucleoside ana-
logue introduced into clinical regimens for cancer thera-
py in 1964, is still one of the most effective drugs for the
treatment of adult acute leukemia. The toxicity of cytara-
bine can be represented by either minor side effects like
exanthema, fever and elevation of hepatic enzymes, that
are relatively frequent, but rarely represent therapeutic
problems or by major adverse effects, including myelo-
suppression, oral and gastrointestinal mucosal damage,
keratoconjunctivitis and neurotoxicity, that can deter-
mine serious clinical problems, sometimes requiring the
definitive interruption of treatment.1,2
Several cancer therapeutic drugs are known to induce
lung toxicity, which may result in a broad spectrum of
clinico-pathologic syndromes with minor to severe
consequences for the patient. Potentially fatal lung tox-
icity has been described in leukemia patients treated
with cytarabine, especially at intermediate to high
doses: this clinical entity, occurring in about 12-20% of
patients, a median of 1-2 weeks (range 1-21 days) after
chemotherapy, usually at initial course, has been
defined  as noncardiogenic pulmonary edema (NCPE).3-
11 It typically presents as a sub-acute syndrome charac-
terised by severe dyspnea, cough, tachypnea, low grade
fever, severe hypoxemia, crackles on thorax ausculta-
tion, and confluent alveolar consolidation on standard
chest X-ray. Diagnosis of this drug-induced respiratory
distress, also called acute lung injury, requires the
exclusion of heart dysfunction and any infectious,
metabolic or cancer-related causes.3-11 Anecdotally, the
association between administration of cytarabine and
the onset of bronchiolitis obliterans organizing pneu-
monia (BOOP), has been reported. BOOP is an uncom-
mon fibrotic diffuse lung disorder, histopathologically
defined as granulation tissue plugging into the lumens
of small airways, extending, in a continuous fashion,
into alveolar ducts and alveoli. It is generally charac-
terised by subacute onset of respiratory symptoms
resolving in the majority of cases (65-80%) with admin-
istration of steroids, but in other cases it may persist,
with chronic and disabling cough and dyspnea, and
may be life threatening, especially in the case of recur-
rence.12-16
We report here three cases of patients affected by
acute myeloid leukemia (AML), treated with chemother-
apeutic regimens including high dose cytarabine, who
developed early onset of fever, mild dyspnea, moderate
hypoxemia on arterial blood gas analysis, and lung infil-
trates documented by high-resolution computerized
tomography (HRCT). Issues of diagnosis and manage-
ment of cytarabine related lung toxicity are discussed
and differences in the clinical features between such
cases and those reported in the literature are reviewed.
Case reports
A 53-year old female patient (case 1) was diagnosed as
having AML M4 to cytochemical FAB classification and
at intermediate risk for normal karyotype to WHO clas-
sification;17,18 she was randomized, according to
GIMEMA (Gruppo Italiano Malattie Ematologiche
dell’Adulto) AML-12 protocol (Arm 2) to receive high
dose cytarabine (3 g/m2 every 12 hours on days +1, +3,
+5, +7) combined with daunorubicin (50 mg/m2 on days
+1, +3, +5), and etoposide (50 mg/m2 on days +1 to +5)
as a remission induction chemoterapeutic regimen. On
day +2, after starting chemotherapy,  the patient became
febrile and presented dry cough; the chest X-ray was
negative and the arterial blood gas analysis performed in
room air was normal (pO2 74 mmHg), but an empirical
antibiotic therapy with piperacillin-tazobactam was
introduced because of severe leukopenia, being the WBC
count 0.6x109/L. Fever persisted up to day +6, raising to
40°C (Figure 1a), but the patient was asymptomatic and
physical examination and vital signs were normal;
though she had not dyspnea, a blood gas analysis was
performed on day +6, consistent with moderate hypox-
emia (pO2 57 mmHg). Thus, on the same day, she under-
went HRCT, that showed bilateral pleural effusions and
areas of patchy consolidations, prevalently on the left
side (Figure 2a). Chemotherapy administration was
stopped and a second line antibiotic therapy with
meropenem and vancomycin was introduced, even
though serological, cultural and molecular examinations
(SCME) of biologic fluids (namely blood, urine, feces cul-
tures, CMV and Aspergillus antigenemia, urinary
Legionella antigen) did not disclose any infectious agent.
Only 24 hours later, the patient became apyretic (Figure
1a), with a significant improvement of blood gas analy-
sis (pO2 87 mmHg). The HRCT performed 72 hours after
discontinuation of chemotherapy showed complete res-
olution of the pathological features described above
(Figure 2b). The two last doses of cytarabine were not
administered.
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A 51-year old male patient (case 2), affected by AML
M6 to FAB classification and at high risk for complex
karyotype and multilineage dysplasia following the
WHO classification,17,18 underwent remission induction
chemotherapeutic regimen according to the same proto-
col previously reported, with high dose cytarabine at
identical schedule. On day +2 after starting chemothera-
py, he became febrile (temperature 38,4°C) (Figure 1b);
he was asymptomatic and chest auscultation resulted
normal but arterial blood gas analysis on room air
showed mild hypoxemia (pO2 67 mmHg) and a small
consolidation area in right para-hilar side was document-
ed on chest X-ray examination. An empirical antibiotic
therapy with piperacillin-tazobactam was introduced
because of mild neutropenia being the neutrophil count
1.3x109/L at onset of fever and, on day +3, a HRCT was
performed, showing moderate bilateral pleural effusion,
bilateral patchy consolidations and a nodular process in
right para-hilar side, surrounded by ground-glass opacity
(Figure 2c). Based upon these features, chemotherapy
administration was temporarily stopped. Twenty four
hours later, the patient became apyretic (Figure 1b) and
the re-evaluation on HRCT, performed 48 hours after the
discontinuation of chemotherapy (on day +5), showed a
slight improvement of the pre-existing features, with the
disappearance of pleural effusions and right basal patchy
consolidation, and size reduction of the other lesions
(Figure 2d). Since the radiological and clinical improve-
ment, with negativity of SCME of biologic fluids (name-
ly blood, urine, feces cultures, CMV and Aspergillus anti-
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Figure 1. Fever charts of
the three leukemic
patients treated with
high dose cytarabine.
Graphs show onset and
subsequent resolution of
fever and the timing of
radiological examina-
tions (X-ray and HRCT),
indicated by arrows
(a,b,c). O hours indicate
the start of administra-
tion of chemotherapy.
genemia), chemotherapy administration was restarted
on day +6, with pre-medication consisting of low dose
dexamethasone (4 mg i.v.) prior to the administration of
high dose cytarabine. The patient completed the
chemotherapy cycle without either fever or respiratory
symptoms.
A 66-year old male patient (case 3), receiving prophy-
laxis with isoniazide for a latent Tuberculosis infection
documented by Quantiferon-TB serologic test, previous-
ly treated for AML with myelodysplastic features accord-
ing to WHO classification,18 relapsed five months after
autologous bone marrow transplantation. The patient
was admitted to our Department in order to undergo a
salvage chemotherapeutic regimen (FLAG) consisting of
cytarabine (2 g/m2 on days +1 to +5), fludarabine (30
mg/m2 on days +1 to +3), G-CSF (5 mcg/kg/day from day
-1 to day +5). On day +1 the patient showed mild dysp-
nea and bilateral inspiratory crackles on chest ausculta-
tion, despite normal pO2 on blood gas analysis. On day
+2 after starting chemotherapy, he became febrile (tem-
perature 38,4°C) (Figure 1c). Blood tests were consistent
with a self-limiting disseminated intravascular coagula-
tion in the absence of bleeding, probably due to
leukemic cell lysis; blood gas analysis on room air docu-
mented moderate hypoxemia (pO2 62 mmHg) and chest
X-ray showed a patchy consolidation in the left lower
lobe and bilateral pleural effusions especially on the left
side (Figure 2e). These features were confirmed by
HRCT on day +3 (Figure 2f). An empirical antibiotic ther-
apy with piperacillin-tazobactam was started, even
though the patient was not neutropenic, being neu-
trophils 4.6x109/L. SCME of biologic fluids (namely
blood, urine, feces cultures, CMV and Aspergillus anti-
genemia) did not disclose any infectious agent.
Furthermore the patient underwent bronchoscopy with
bronchoalveolar lavage (BAL) but SCME resulted nega-
tive also on BAL samples, including tests for
Mycobacterial infection. From day +3 the patient
became apyretic (Figure 1c) and asymptomatic, without
stopping administration of chemotherapy and a chest X-
ray, performed 72 hours later, showed complete resolu-
tion of the radiological features described above (Figure
2g). The treatment protocols have been approved by our
Institutional Ethics Committee, and all three patients
have given written informed consent.
Discussion
We report here three patients, affected by AML, who
developed fever, mild dyspnea, moderate hypoxemia on
blood gas analysis, lung infiltrates, consisting of patchy
consolidation areas and pleural effusions, documented
either by chest X-ray or by HRCT, 24 hours after the
administration of high dose cytarabine. The disappear-
ance of symptoms and the complete resolution of radio-
logical signs documented by HRCT were obtained in 48-
72 hours, while drug administration was continued in
one case, but delayed by 72 hours and stopped before
the last dose in the two others, respectively. Cytarabine-
induced lung toxicity is probably related to a cytokine-
mediated mechanism involving tumor necrosis factor-
alpha and platelet activating factor, which determine
inflammatory response with alveolar damage and
increased vascular permeability.19 Diagnosis of cytara-
bine-induced lung toxicity is an exercise of exclusion of
several other causes of lung infiltrates, such as heart fail-
ure and metabolic dysfunctions (renal failure, hypoalbu-
minemia, pancreatitis),11 leukemic infiltrates, even in
absence of leukocytosis or peripheral blastosis,20 and
infectious causes,21 including bacterial and fungal agents,
Pneumocystis carinii, and, although rarely, also viral infec-
tions.22 In our series, the above mentioned causes were
excluded, and no infectious agents were disclosed by
biologic fluid SCME (Table 1). On the other hand, the
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Figure 2. Radiological examinations in the three leukemic
patients receiving high dose cytarabine. Early lung infiltrates in
leukemic patients characterised by chest X-ray and/or HRCT
(a,c,e,f); complete and spontaneous resolution in 48-72 hours
(b,d,g).
prompt resolution of the febrile condition as well as the
very early and complete disappearance of the radiologi-
cal findings, as documented by HRCT, cannot be
ascribed to the few day empirical antibiotic therapy. 
The radiological signs in our three cases resemble
those typically detected in both NCPE and BOOP, which
can be characterised by signs of alveolar or interstitial
opacification, surrounded, sometimes, by ground glass
areas, and pleural effusions. The real difference between
our cases and those reported in the literature is in the
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Table 1. Clinical evaluation of possible causes of lung infiltrates (cardiac or metabolic dysfunctions, infectious agents) other than cytara-
bine, in our three leukemic patients.
PATIENTS Scme Echocardiogram Ecg Renal function Albuminemia Pancreatic
on biologic before starting at presentation at presentation on the day before enzymes
fluids chemotherapy (EF %) of symptoms of symptoms starting (U/L)
Creatinine (mg/dL) chemotherapy (g/dL)
Pt 1 Negative Normal Normal Normal Normal Amilase 56,
(70%) (0,84) (4,5) Lipase NA
Pt 2 Negative Normal Normal Normal Normal Amilase 38
(60%) (0,85) (3,6) Lipase 18
Pt 3 Negative* Normal Normal Normal Normal Amilase 16
(55%) (0,80) (3,9) Lipase NA
SCME indicates serological, cultural and molecular examination of biologic fluids (blood, urine, feces cultures, CMV and Aspergillus anti-
genemia). *These tests have been performed also on BAL specimens in Pt 3. EF %: ejection fraction. ECG: electrocardiogram. NA: Not
Available. Normal values in Our Laboratory: Creatinine 0,6-1,4 mg/dL for male, 0,6-1,2 mg/dL for female; Albumine 3,5-5 g/dL; Amilase
1-100 U/L; Lipase 1-60 U/L.
Table 2. Revision of the clinical data available from cases of cytarabine-related lung toxicity, previously reported in the literature.
Patients Median age Status of Median time (days) Clinical
Reference presenting (years) hematologic Cytarabine dosage of onset of symptoms outcome
toxicity (N) of patients (range) disease (N) from start of (N)
chemotherapy (range)
Haupt et al. 10 early; 18 39 (1-85) 28 REL Intermediate 0-3; 4-30 28 deaths
1981 late occurrence (7,5-30 mg/kg/day) (autoptic data)
Andersson 16 35 (16-68) 16 REL High (3 g/m2 every 12 16 (2-21) 15 recoveries,
et al. 1985 hours for 4-12 doses) 1 death.*
Andersson 14 39 (22-66) 14 REL High (3 g/m2  every 6 8 (1-29) 4 recoveries,
et al. 1990 to 12 hours for 6 to 12 10 deaths
doses OR 3 g/m2 every
12 hours for 2 doses,
followed by 1,5 g/m2 over
24 hours for 3-4 days)
Salvucci 2 14, 31 1 PR1 REL High 1, 7 2 recoveries.*
et al. 2000 (4 g/day for 5 days)
Tham et al. 15 29(15-57) 15 first line Intermediate (1 every 16 (8-20) 13 recoveries,
1987 therapy 3 g/m2 12 hours for 6 2 deaths.*
days) High (3 g/m2 every
12 hours for 4 days)
Jehn et al. 7 40 (17-64) 7 REL/REF Intermediate (1 g/m2 NA (1-14) 3 recoveries,
1988 every 12 hours for 6 4 deaths
days) High (3 g/m2 every
12 hours for 4 days)
Shearer 5 NA (4-12) 5 REL Intermediate/High 8 (3-38**) 2 recoveries,
et al. 1994 (1.0-1.5 g/m2 over 3 deaths
24 hours for 5 days)
Our cases 3 53, 51, 66 2 first line High (3 g/m2 every 12 1 3 recoveries.*
2007 therapy, 1 REL hours on day 1, 3, 5, 7
or 2 for g/m2 5 days)
*indicates that some patients of the series received corticosteroids. **indicate that one patient presented respiratory symptoms 38
days after the first course of cytarabine, but a second course had been already administered just before the onset of symptoms. N: num-
ber of cases; PR: partial remission; REL: relapsed; REF: refractory; NA: not available.
clinical features.11,14 All our patients developed a sudden
onset of symptoms after starting receiving the drug, but,
despite the severity of radiological findings, the symp-
toms have been quite smouldering, with mild dyspnea
and moderate hypoxemia on blood gas analysis. Lung
toxicity appeared self limiting, neither requiring the drug
discontinuation nor the corticosteroid infusion in case 3,
while only low dose dexamethasone was administered
to prevent fever in case 2. This clinical behaviour clearly
differs from the clinical course in cases of NCPE, a poten-
tially fatal lung toxicity, with abrupt onset of severe
symptoms and which, if not fatal, can be reversed only
with discontinuation of the administration of cytarabine
and immediate start of intensive support treatment,
including high dose systemic steroids, mechanical venti-
lation and pressure support.11 On the other hand, the
clinical course in our cases also differs from that in cases
of BOOP, in which spontaneous, slow improvement
occurs occasionally, but often corticosteroid treatment is
required. In the latter instance the response to corticos-
teroids is impressive, because clinical manifestations
improve within 48 hours, but complete resolution of radi-
ographic pulmonary infiltrates takes several weeks.14-16
There are no evident epidemiologic differences
between our three patients and the previously reported
patients in the literature regarding either age or dosage of
cytarabine. Most of the reported patients were affected
with relapsed leukemia (Table 2), so that we cannot
exclude that heavily pre-treated patients could be more
exposed to a possibly severe lung toxicity. From the
review of the literature, it appears that cytarabine-relat-
ed lung toxicity occurs more frequently in patients with
relapsed leukemia (72 out of 90 reported cases), than in
patients with de novo leukemia (18 out of 90 patients). In
the former patient group, a more severe, often fatal,
course is observed (46 out of 72 patients); in the latter
group, only 2 out of 18 patients died from lung toxicity.
Of note, while most of the reported patients underwent
standard chest X-ray examinations, our patients under-
went HRCT at a very early phase, which probably
allowed us to better characterise severe radiological find-
ings, in the absence of a corresponding severity of clini-
cal symptoms. Thus, the incidence of cytarabine-related
lung infiltrates may be underestimated, so that we rec-
ommend the early performance of HRCT in leukemic
patients treated with intermediate to high dose cytara-
bine at onset of respiratory symptoms, even if of mild
entity. As far as the therapeutic approach to patients
with cytarabine-related lung toxicity is concerned, it is
not possible to define a formal management guideline,
simply based on our observations and on the revised
data from the literature. Decisions about definitive dis-
continuation of cytarabine or introduction of systemic
steroid therapy, that could determine dramatic improve-
ment and favorable outcome, also in the most critical
patients,11,23 should be based upon a careful evaluation of
the clinical status (respiratory symptoms, fever, blood
gas analysis and state of hematologic disease). The role
of corticosteroids or any other therapeutic support in this
clinical setting should be evaluated in clinical trials.
However, the reported high incidence of cytarabine-
related lung toxicity in relapsed leukaemia patients, may
suggest to introduce pre-medication with low dose dex-
amethasone in this patient subgroup.
In conclusion, cytarabine-related toxicity should be
considered among the possible causes of lung infiltrates
in patients with leukemia, also in neutropenic phase.7,9,10
The clinical entity we report in our three patients is char-
acterised by a more indolent behaviour and a benign
clinical outcome, compared with previously reported
similar cases. Our case descriptions widen the spectrum
of clinical features of cytarabine-related toxicity which
might be encountered in leukemic patients.
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